About this Journal Submit a Manuscript Table of Contents
Cholesterol
Volume 2011 (2011), Article ID 496925, 9 pages
http://dx.doi.org/10.1155/2011/496925
Review Article

The Role of High-Density Lipoproteins in Reducing the Risk of Vascular Diseases, Neurogenerative Disorders, and Cancer

1Department of Pathology, Faculty of Medical Sciences, University of the West Indies, Mona Campus, Kingston 7, Jamaica
2College of Health Sciences, University of Technology, 237 Old Hope Road, Kingston 6, Jamaica
3Principal's Office, University of Technology, 237 Old Hope Road, Kingston 6, Jamaica
4Department of Medicine, Faculty of Medical Sciences, University of the West Indies, Kingston 7, Jamaica

Received 4 September 2010; Accepted 4 November 2010

Academic Editor: Gerhard M. Kostner

Copyright © 2011 Donovan McGrowder et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Barter, J. Kastelein, and J. Kastelein, “High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions,” Atherosclerosis, vol. 168, no. 2, pp. 195–211, 2003. View at Publisher · View at Google Scholar
  2. P. K. Shah, S. Kaul, J. Nilsson, and B. Cercek, “Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I,” Circulation, vol. 104, no. 19, pp. 2376–2383, 2001.
  3. J. J. Albers, J. H. Tollefson, C. H. Chen, and A. Steinmetz, “Isolation and characterization of human plasma lipid transfer proteins,” Arteriosclerosis, vol. 4, no. 1, pp. 49–58, 1984.
  4. E. R. Skinner, “High-density lipoprotein subclasses,” Current Opinion in Lipidology, vol. 5, no. 3, pp. 241–247, 1994.
  5. A. M. Gotto, “Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report,” Circulation, vol. 103, no. 17, pp. 2213–2218, 2001. View at Scopus
  6. H. Drexel, “Reducing risk by raising HDL-cholesterol: the evidence,” European Heart Journal, Supplement, vol. 8, pp. F23–F29, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. P. P. Toth, “High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies,” American Journal of Cardiology, vol. 96, no. 9, pp. 50K–58K, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. D. J. Gordon, J. L. Probstfield, and J. L. Probstfield, “High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies,” Circulation, vol. 79, no. 1, pp. 8–15, 1989.
  9. W. P. Castelli, “Cholesterol and lipids in the risk of coronary artery disease. The Framingham Heart Study,” Canadian Journal of Cardiology, vol. 4, supplement A, pp. 5–10, 1988. View at Scopus
  10. U. Goldbourt, S. Yaari, and J. H. Medalie, “Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 17, no. 1, pp. 107–113, 1997. View at Scopus
  11. M. J. Stampfer, F. M. Sacks, S. Salvini, W. C. Willett, and C. H. Hennekens, “A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction,” The New England Journal of Medicine, vol. 325, no. 6, pp. 373–381, 1991. View at Scopus
  12. G. Assmann, P. Cullen, and H. Schulte, “The Münster Heart Study (PROCAM). Results of follow-up at 8 years,” European Heart Journal, vol. 19, pp. A2–A11, 1998. View at Scopus
  13. W. B. Kannel, “Range of serum cholesterol values in the population developing coronary artery disease,” American Journal of Cardiology, vol. 76, no. 9, pp. 69C–77C, 1995. View at Scopus
  14. D. M. Capuzzi, J. R. Guyton, J. M. Morgan, A. C. Goldberg, R. A. Kreisberg, O. A. Brusco, and J. Brody, “Efficacy and safety of an extended-release niacin (Niaspan): a long-term study,” American Journal of Cardiology, vol. 82, no. 12, pp. 74U–81U, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. J. R. Guyton, A. C. Goldberg, R. A. Kreisberg, D. L. Sprecher, H. R. Superko, and C. M. O'Connor, “Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia,” American Journal of Cardiology, vol. 82, no. 6, pp. 737–743, 1998. View at Scopus
  16. J. M. McKenney, L. S. McCormick, S. Weiss, M. Koren, S. Kafonek, and D. M. Black, “A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia,” American Journal of Medicine, vol. 104, no. 2, pp. 137–143, 1998. View at Publisher · View at Google Scholar
  17. W. P. Castelli, R. J. Garrison, P. W. F. Wilson, et al., “Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study,” Journal of the American Medical Association, vol. 256, no. 20, pp. 2835–2838, 1986.
  18. A. J. Taylor, H. J. Lee, and L. E. Sullenberger, “The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3,” Current Medical Research and Opinion, vol. 22, no. 11, pp. 2243–2250, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. H. B. Rubins, S. J. Robins, and S. J. Robins, “Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol,” New England Journal of Medicine, vol. 341, no. 6, pp. 410–418, 1999. View at Publisher · View at Google Scholar · View at PubMed
  20. M. H. Frick, O. Elo, and K. Haapa, “Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease,” New England Journal of Medicine, vol. 317, no. 20, pp. 1237–1245, 1987. View at Scopus
  21. J. P. Després, I. Lemieux, and S. J. Robins, “Role of fibric acid derivatives in the management of risk factors for coronary heart disease,” Drugs, vol. 64, no. 19, pp. 2177–2198, 2004. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Császár, “Hypertriglyceridemia, the coronary heart disease risk marker "solved",” Acta Physiologica Hungarica, vol. 92, no. 2, pp. 109–120, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. T. Meade, R. Zuhrie, C. Cook, and J. Cooper, “Bezafibrate in men with lower extremity arterial disease: randomised controlled trial,” British Medical Journal, vol. 325, no. 7373, pp. 1139–1141, 2002. View at Scopus
  24. A. Keech, R. J. Simes, P. Barter, et al., “Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial,” The Lancet, vol. 366, no. 9500, pp. 1849–1861, 2005.
  25. G. F. Lewis and D. J. Rader, “New insights into the regulation of HDL metabolism and reverse cholesterol transport,” Circulation Research, vol. 96, no. 12, pp. 1221–1232, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  26. J. G. Robinson and M. H. Davidson, “Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport,” Future Lipidology, vol. 2, no. 3, pp. 285–301, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. M. J. Chapman, G. Assmann, J. C. Fruchart, J. Shepherd, and C. Sirtori, “Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid—a position paper developed by the European Consensus Panel on HDL-C,” Current Medical Research and Opinion, vol. 20, no. 8, pp. 1253–1268, 2004. View at Scopus
  28. A. D. Watson, J. A. Berliner, S. Y. Hama, B. N. La Du, K. F. Faull, A. M. Fogelman, and M. Navab, “Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein,” Journal of Clinical Investigation, vol. 96, no. 6, pp. 2882–2891, 1995. View at Scopus
  29. B. Mackness, P. Durrington, P. McElduff, J. Yarnell, N. Azam, M. Watt, and M. Mackness, “Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study,” Circulation, vol. 107, no. 22, pp. 2775–2779, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. C. C. Hedrick, S. R. Thorpe, and S. R. Thorpe, “Glycation impairs high-density lipoprotein function,” Diabetologia, vol. 43, no. 3, pp. 312–320, 2000. View at Scopus
  31. C. A. Abbott, M. I. Mackness, S. Kumar, A. J. Boulton, and P. N. Durrington, “Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 15, no. 11, pp. 1812–1818, 1995. View at Scopus
  32. J. R. Nofer, B. Kehrel, M. Fobker, B. Levkau, G. Assmann, and A. V. Eckardstein, “HDL and arteriosclerosis: beyond reverse cholesterol transport,” Atherosclerosis, vol. 161, no. 1, pp. 1–16, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. N. N. Chan, H. M. Colhoun, and P. Vallance, “Cardiovascular risk factors as determinants of endothelium-dependent and endothelium-independent vascular reactivity in the general population,” Journal of the American College of Cardiology, vol. 38, no. 7, pp. 1814–1820, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. G. Lupattelli, S. Marchesi, and S. Marchesi, “Direct association between high-density lipoprotein cholesterol and endothelial function in hyperlipemia,” American Journal of Cardiology, vol. 90, no. 6, pp. 648–650, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. S. F. O'Brien, G. F. Watts, D. A. Playford, V. Burke, D. N. O'Neal, and J. D. Best, “Low-density lipoprotein size, highdensity lipoprotein concentration, and endothelial dysfunction in non-insulindependent diabetes,” Diabetic Medicine, vol. 14, no. 11, pp. 974–978, 1997. View at Publisher · View at Google Scholar · View at Scopus
  36. X. Y. Zhang, S. P. Zhao, X. P. Li, M. Gao, and QI. C. Zhou, “Endothelium-dependent and -independent functions are impaired in patients with coronary heart disease,” Atherosclerosis, vol. 149, no. 1, pp. 19–24, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. M. G. Conlan, A. R. Folsom, A. Finch, C. E. Davis, P. Sorlie, G. Marcucci, and K. K. Wu, “Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study,” Thrombosis and Haemostasis, vol. 70, no. 3, pp. 380–385, 1993. View at Scopus
  38. N. F. Boyd and V. McGuire, “Evidence of association between plasma high-density lipoprotein cholesterol and risk factors for breast cancer,” Journal of the National Cancer Institute, vol. 82, no. 6, pp. 460–468, 1990. View at Scopus
  39. D. Gospodarowicz, G. M. Lui, and R. Gonzalez, “High-density lipoproteins and the proliferation of human tumor cells maintained on extracellular matrix-coated dishes and exposed to defined medium,” Cancer Research, vol. 42, no. 9, pp. 3704–3713, 1982. View at Scopus
  40. M. Rotheneder and G. M. Kostner, “Effects of low- and high-density lipoproteins on the proliferation of human breast cancer cells in vitro: differences between hormone-dependent and hormone-independent cell lines,” International Journal of Cancer, vol. 43, no. 5, pp. 875–879, 1989. View at Scopus
  41. J. R. Nofer, R. Junker, and R. Junker, “High density lipoproteins induce cell cycle entry in vascular smooth muscle cells via mitogen activated protein kinase-dependent pathway,” Thrombosis and Haemostasis, vol. 85, no. 4, pp. 730–735, 2001. View at Scopus
  42. J. R. Nofer, B. Levkau, and B. Levkau, “Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids,” Journal of Biological Chemistry, vol. 276, no. 37, pp. 34480–34485, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. M. L. Knapp, S. Al-Sheibani, and P. G. Riches, “Alterations of serum lipids in breast cancer: effects of disease activity, treatment, and hormonal factors,” Clinical Chemistry, vol. 37, no. 12, pp. 2093–2101, 1991. View at Scopus
  44. A. P. Hoyer and G. Engholm, “Serum lipids and breast cancer risk: a cohort study of 5,207 Danish women,” Cancer Causes and Control, vol. 3, no. 5, pp. 403–408, 1992. View at Scopus
  45. M. Gaard, S. Tretli, and F. Urdal, “Risk of breast cancer in relation to blood lipids: a prospective study of 31,209 Norwegian women,” Cancer Causes and Control, vol. 5, no. 6, pp. 501–509, 1994. View at Publisher · View at Google Scholar · View at Scopus
  46. I. A. Bani, C. M. Williams, P. S. Boulter, and J. W. T. Dickerson, “Plasma lipids and prolactin in patients with breast cancer,” British Journal of Cancer, vol. 54, no. 3, pp. 439–446, 1986. View at Scopus
  47. E. Kokoglu, I. Karaarslan, H. M. Karaarslan, and H. Baloglu, “Alterations of serum lipids and lipoproteins in breast cancer,” Cancer Letters, vol. 82, no. 2, pp. 175–178, 1994. View at Publisher · View at Google Scholar · View at Scopus
  48. L. E. Schreier, G. A. Berg, F. M. Basilio, G. I. Lopez, A. E. Etkin, and R. L. Wikinski, “Lipoprotein alterations, abdominal fat distribution and breast cancer,” Biochemistry and Molecular Biology International, vol. 47, no. 4, pp. 681–690, 1999. View at Scopus
  49. G. Ray and S. A. Husain, “Role of lipids, lipoproteins and vitamins in women with breast cancer,” Clinical Biochemistry, vol. 34, no. 1, pp. 71–76, 2001. View at Publisher · View at Google Scholar · View at Scopus
  50. A. S. Furberg, M. B. Veierød, T. Wilsgaard, L. Berstein, and I. Thune, “Serum high density lipoprotein cholesterol, metabolic profile, and breast cancer risk,” Journal of the National Cancer Institute, vol. 96, no. 15, pp. 1152–1160, 2004. View at Scopus
  51. P. G. Moorman, B. S. Hulka, R. A. Hiatt, N. Krieger, B. Newman, J. H. Vogelman, and N. Orentreich, “Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status,” Cancer Epidemiology Biomarkers and Prevention, vol. 7, no. 6, pp. 483–488, 1998. View at Scopus
  52. K. Siemianowicz, J. Gminski, and J. Gminski, “Serum HDL cholesterol concentration in patients with squamous cell and small cell lung cancer,” International Journal of Molecular Medicine, vol. 6, no. 3, pp. 307–311, 2000. View at Scopus
  53. S. Umeki, “Decreases in serum cholesterol levels in advanced lung cancer,” Respiration, vol. 60, no. 3, pp. 178–181, 1993. View at Scopus
  54. S. Dessi, B. Batetta, and B. Batetta, “Altered pattern of lipid metabolism in patients with lung cancer,” Oncology, vol. 49, no. 6, pp. 436–441, 1992. View at Scopus
  55. A. M. Fiorenza, A. Branchi, and D. Sommariva, “Serum lipoprotein profile in patients with cancer. A comparison with non-cancer subjects,” International Journal of Clinical and Laboratory Research, vol. 30, no. 3, pp. 141–145, 2000. View at Publisher · View at Google Scholar · View at Scopus
  56. A. M. Kucharska-Newton, W. D. Rosamond, J. C. Schroeder, A. M. McNeill, J. Coresh, and A. R. Folsom, “HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study,” Lung Cancer, vol. 61, no. 3, pp. 292–300, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  57. J. Ahn, U. Lim, S. J. Weinstein, A. Schatzkin, R. B. Hayes, J. Virtamo, and D. Albanes, “Prediagnostic total and high-density lipoprotein cholesterol and risk of cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 11, pp. 2814–2821, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  58. A. R. Tall, “An overview of reverse cholesterol transport,” European Heart Journal, vol. 19, pp. A31–A35, 1998. View at Scopus
  59. A. Von Eckardstein, M. Hersberger, and L. Rohrer, “Current understanding of the metabolism and biological actions of HDL,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 8, no. 2, pp. 147–152, 2005. View at Scopus
  60. E. Esteve, W. Ricart, and J. M. Fernández-Real, “Dyslipidemia and inflammation: an evolutionary conserved mechanism,” Clinical Nutrition, vol. 24, no. 1, pp. 16–31, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. E. A. Engels, “Inflammation in the development of lung cancer: epidemiological evidence,” Expert Review of Anticancer Therapy, vol. 8, no. 4, pp. 605–615, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  62. R. J. Spiegel, E. J. Schaefer, I. T. Magrath, and B. K. Edwards, “Plasma lipid alterations in leukemia and lymphoma,” American Journal of Medicine, vol. 72, no. 5, pp. 775–782, 1982. View at Scopus
  63. J. D. Blackman, V. G. Cabana, and T. Mazzone, “The acute-phase response and associated lipoprotein abnormalities accompanying lymphoma,” Journal of Internal Medicine, vol. 233, no. 2, pp. 201–204, 1993. View at Scopus
  64. U. Lim, T. Gayles, and T. Gayles, “Serum high-density lipoprotein cholesterol and risk of non-hodgkin lymphoma,” Cancer Research, vol. 67, no. 11, pp. 5569–5574, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  65. M. Navab, G. M. Ananthramaiah, and G. M. Ananthramaiah, “The double jeopardy of HDL,” Annals of Medicine, vol. 37, no. 3, pp. 173–178, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  66. U. J. F. Tietge, C. Maugeais, W. Cain, and D. J. Rader, “Acute inflammation increases selective uptake of HDL cholesteryl esters into adrenals of mice overexpressing human sPLA,” American Journal of Physiology, vol. 285, no. 2, pp. E403–E411, 2003. View at Scopus
  67. L. E. Spieker, F. Ruschitzka, T. F. Lüscher, and G. Noll, “HDL and inflammation in atherosclerosis,” Current Drug Targets Immune, Endocrine and Metabolic Disorders, vol. 4, no. 1, pp. 51–57, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. G. W. Cockerill, T. Y. Huehns, A. Weerasinghe, C. Stocker, P. G. Lerch, N. E. Miller, and D. O. Haskard, “Elevation of plasma high-density lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation,” Circulation, vol. 103, no. 1, pp. 108–112, 2001. View at Scopus
  69. B. J. Ansell, K. E. Watson, A. M. Fogelman, M. Navab, and G. C. Fonarow, “High-density lipoprotein function: recent advances,” Journal of the American College of Cardiology, vol. 46, no. 10, pp. 1792–1798, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  70. P. J. Whitehouse, C. G. Sciulli, and R. M. Mason, “Dementia drug development: use of information systems to harmonize global drug development,” Psychopharmacology Bulletin, vol. 33, no. 1, pp. 129–133, 1997. View at Scopus
  71. I. J. Martins, E. Hone, and E. Hone, “Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease,” Molecular Psychiatry, vol. 11, no. 8, pp. 721–736, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  72. J. H. Xuereb, C. Brayne, and C. Brayne, “Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders,” Annals of the New York Academy of Sciences, vol. 903, pp. 490–496, 2000. View at Scopus
  73. G. P. Eckert, C. Kirsch, S. Leutz, W. G. Wood, and W. E. Müller, “Cholesterol modulates amyloid beta-peptide's membrane interactions,” European Archives of Psychiatry and Clinical Neuroscience, vol. 252, no. 2, pp. 63–67, 2003.
  74. A. R. Koudinov and N. V. Koudinova, “Essential role for cholesterol in synaptic plasticity and neuronal degeneration,” The FASEB Journal, vol. 15, no. 10, pp. 1858–1860, 2001. View at Scopus
  75. M. Guglielmotto, L. Giliberto, E. Tamagno, and M. Tabaton, “Oxidative stress mediates the pathogenic effect of different Alzheimer's disease risk factors,” Front Aging Neuroscience, vol. 9, no. 2, p. 3, 2010.
  76. M. Dominique Ashen and R. S. Blumenthal, “Low HDL cholesterol levels,” New England Journal of Medicine, vol. 353, no. 12, pp. 1252–1260, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. M. A. Ward, C. M. Carlsson, M. A. Trivedi, M. A. Sager, and S. C. Johnson, “The effect of body mass index on global brain volume in middle-aged adults: a cross sectional study,” BMC Neurology, vol. 5, Article ID 23, 2005. View at Publisher · View at Google Scholar · View at PubMed
  78. A. F. Kramer, K. I. Erickson, and S. J. Colcombe, “Exercise, cognition, and the aging brain,” Journal of Applied Physiology, vol. 101, no. 4, pp. 1237–1242, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. N. Barzilai, G. Atzmon, C. A. Derby, J. M. Bauman, and R. B. Lipton, “A genotype of exceptional longevity is associated with preservation of cognitive function,” Neurology, vol. 67, no. 12, pp. 2170–2175, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. A. Singh-Manoux, D. Gimeno, M. Kivimaki, E. Brunner, and M. G. Marmot, “Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife the whitehall II study,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 8, pp. 1556–1562, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. S. E. Wahrle, H. Jiang, and H. Jiang, “Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease,” Journal of Clinical Investigation, vol. 118, no. 2, pp. 671–682, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. O. F. Olesen and L. Dagø, “High density lipoprotein inhibits assembly of amyloid β-peptides into fibrils,” Biochemical and Biophysical Research Communications, vol. 270, no. 1, pp. 62–66, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. S. Lesné, T. K. Ming, and T. K. Ming, “A specific amyloid-β protein assembly in the brain impairs memory,” Nature, vol. 440, no. 7082, pp. 352–357, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  84. J. Hardy and K. Cullen, “Amyloid at the blood vessel wall,” Nature Medicine, vol. 12, no. 7, pp. 756–757, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. A. Kontush, “Amyloid-β: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease,” Free Radical Biology and Medicine, vol. 31, no. 9, pp. 1120–1131, 2001. View at Publisher · View at Google Scholar · View at Scopus
  86. A. B. Reiss, K. A. Siller, M. M. Rahman, E. S. L. Chan, J. Ghiso, and M. J. De Leon, “Cholesterol in neurologic disorders of the elderly: stroke and Alzheimer's disease,” Neurobiology of Aging, vol. 25, no. 8, pp. 977–989, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. M. Michikawa, “Cholesterol paradox: is high total or low HDL cholesterol level a risk for Alzheimer's disease?” Journal of Neuroscience Research, vol. 72, no. 2, pp. 141–146, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. H. Wolf, A. Hensel, T. Arendt, M. Kivipelto, B. Winblad, and H. J. Gertz, “Serum lipids and hippocampal volume: the link to Alzheimer's disease?” Annals of Neurology, vol. 56, no. 5, pp. 745–748, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. M. Kivipelto, T. Ngandu, T. Laatikainen, B. Winblad, H. Soininen, and J. Tuomilehto, “Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study,” Lancet Neurology, vol. 5, no. 9, pp. 735–741, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. G. Zuliani, A. Ble, and A. Ble, “Lipoprotein profile in older patients with vascular dementia and Alzheimer's disease,” BMC Geriatrics, vol. 1, pp. 1–5, 2001. View at Publisher · View at Google Scholar
  91. M. Kuriyama, K. Takahashi, T. Yamano, Y. Hokezu, S. Togo, M. Osame, and T. Igakura, “Low levels of serum apolipoprotein A I and A II in senile dementia,” Japanese Journal of Psychiatry and Neurology, vol. 48, no. 3, pp. 589–593, 1994. View at Scopus
  92. T. J. Muckle and J. R. Roy, “High-density lipoprotein cholesterol in differential diagnosis of senile dementia,” The Lancet, vol. 1, no. 8439, pp. 1191–1193, 1985. View at Scopus
  93. E. Van Exel, A. J. M. De Craen, and A. J. M. De Craen, “Association between high-density lipoprotein and cognitive impairment in the oldest old,” Annals of Neurology, vol. 51, no. 6, pp. 716–721, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  94. R. L. Sacco, R. T. Benson, and R. T. Benson, “High-density lipoprotein cholesterol and ischemic stroke in the elderly the northern manhattan stroke study,” Journal of the American Medical Association, vol. 285, no. 21, pp. 2729–2735, 2001. View at Scopus
  95. S. N. Romas, M. X. Tang, L. Berglund, and R. Mayeux, “APOE genotype, plasma lipids, lipoproteins, and AD in community elderly,” Neurology, vol. 53, no. 3, pp. 517–521, 1999. View at Scopus
  96. C. Reitz, M. X. Tang, J. Luchsinger, and R. Mayeux, “Relation of plasma lipids to Alzheimer disease and vascular dementia,” Archives of Neurology, vol. 61, no. 5, pp. 705–714, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. G. Li, J. B. Shofer, and J. B. Shofer, “Serum cholesterol and risk of Alzheimer disease: a community-based cohort study,” Neurology, vol. 65, no. 7, pp. 1045–1050, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  98. R. D. Abbott, D. S. Sharp, C. M. Burchfiel, J. D. Curb, B. L. Rodriguez, A. A. Hakim, and K. Yano, “Cross-sectional and longitudinal changes in total and high-density-lipoprotein cholesterol levels over a 20-year period in elderly men: the Honolulu Heart Program,” Annals of Epidemiology, vol. 7, no. 6, pp. 417–424, 1997. View at Scopus
  99. A. Ferrara, E. Barrett-Connor, and J. Shan, “Total, LDL, and HDL cholesterol decrease with age in older men and women: the Rancho Bernardo Study 1984–1994,” Circulation, vol. 96, no. 1, pp. 37–43, 1997. View at Scopus
  100. M. Kawano, M. Kawakami, M. Otsuka, H. Yashima, T. Yaginuma, and A. Ueki, “Marked decrease of plasma apolipoprotein AI and AII in Japanese patients with late-onset non-familial Alzheimer's disease,” Clinica Chimica Acta, vol. 239, no. 2, pp. 209–211, 1995. View at Publisher · View at Google Scholar · View at Scopus
  101. A. Merched, Y. Xia, S. Visvikis, J. M. Serot, and G. Siest, “Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease,” Neurobiology of Aging, vol. 21, no. 1, pp. 27–30, 2000. View at Publisher · View at Google Scholar · View at Scopus
  102. J. S. Saczynski, L. White, R. L. Peila, B. L. Rodriguez, and L. J. Launer, “The relation between apolipoprotein A-I and dementia: the honolulu-asia aging study,” American Journal of Epidemiology, vol. 165, no. 9, pp. 985–992, 2007. View at Publisher · View at Google Scholar · View at PubMed